We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

46 hedge funds and large institutions have $90.1M invested in VistaGen Therapeutics in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 15 increasing their positions, 2 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

826% more call options, than puts

Call options by funds: $5.29M | Put options by funds: $571K

650% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 2

472% more capital invested

Capital invested by funds: $15.7M → $90.1M (+$74.3M)

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

35% more funds holding

Funds holding: 34 → 46 (+12)

33.07% more ownership

Funds ownership: 32.09% → 65.16% (+33%)

Holders
46
Holders Change
+12
Holders Change %
+35.29%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
15
Reduced
2
Closed
12
Calls
$5.29M
Puts
$571K
Net Calls
+$4.71M
Net Calls Change
+$589K

Top Buyers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
+$10.1M
2
BI
BVF Inc
California
+$7.57M
3
GPP
Great Point Partners
Connecticut
+$7.03M
4
NCM
Nantahala Capital Management
Connecticut
+$6.88M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$5.98M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$1.2M
2
SSA
Schonfeld Strategic Advisors
New York
-$726K
3
Group One Trading
Group One Trading
Illinois
-$285K
4
MA
MYDA Advisors
New York
-$262K
5
BFM
Boothbay Fund Management
New York
-$246K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$119K +$87.3K +23,077 New
Jane Street
27
Jane Street
New York
$113K +$83K +21,940 New
Bank of America
28
Bank of America
North Carolina
$99.7K +$71K +18,766 +2,965%
VF
29
Virtu Financial
New York
$80K +$58.7K +15,524 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$78K +$57.4K +15,171 New
Simplex Trading
31
Simplex Trading
Illinois
$63K +$37.5K +9,907 +402%
Osaic Holdings
32
Osaic Holdings
Arizona
$53.8K +$21.4K +5,653 +117%
Janney Montgomery Scott
33
Janney Montgomery Scott
Pennsylvania
$51K +$37.8K +10,000 New
TRCT
34
Tower Research Capital (TRC)
New York
$47.8K +$35.2K +9,298 New
GWSG
35
GPS Wealth Strategies Group
Colorado
$43.4K – – –
Carson Wealth (CWM LLC)
36
Carson Wealth (CWM LLC)
Nebraska
$13K – – –
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$7K -$5.38K -1,423 -50%
BL
38
BFSG LLC
California
$5.14K +$3.78K +1,000 New
First Manhattan
39
First Manhattan
New York
$1.71K +$1.26K +333 New
Wells Fargo
40
Wells Fargo
California
$1.07K +$530 +140 +206%
CG
41
Cutler Group
California
$1K +$757 +200 New
UBS Group
42
UBS Group
Switzerland
$601 -$5.23K -1,381 -92%
EWA
43
EverSource Wealth Advisors
Alabama
$452 – – –
Jones Financial Companies
44
Jones Financial Companies
Missouri
$411 +$303 +80 New
FG
45
Fairman Group
Pennsylvania
$149 +$110 +29 New
JP Morgan Chase
46
JP Morgan Chase
New York
$82 – – –
IC
47
Ikarian Capital
Texas
– -$1.2M -229,100 Closed
SSA
48
Schonfeld Strategic Advisors
New York
– -$726K -138,500 Closed
Group One Trading
49
Group One Trading
Illinois
– -$285K -75,305 Closed
MA
50
MYDA Advisors
New York
– -$262K -50,000 Closed
1
2
3

VTGN Hedge Fund Activity: Q4 2023 in Review

46 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2023, worth a combined $90.1M — up 472% from $15.7M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new VTGN positions and 12 closed out — a net gain of 12 holders — while 15 added to existing stakes and 2 trimmed.

The largest buyer was TCG Crossover Management, opening a new position worth an estimated $10.1M. The largest seller was Ikarian Capital, exiting entirely with an estimated $1.2M sold.

  • 46 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2023, up from 34 in Q3 2023.
  • Funds reported $90.1M of VistaGen Therapeutics stock for Q4 2023, up 472% quarter-over-quarter.
  • 24 funds opened new VistaGen Therapeutics positions in Q4 2023 and 12 closed out, a net change of +12 holders.
  • The largest VistaGen Therapeutics buyer in Q4 2023 was TCG Crossover Management, an estimated $10.1M added.
  • The largest VistaGen Therapeutics seller in Q4 2023 was Ikarian Capital, an estimated $1.2M sold.

Based on aggregated 13F filings for Q4 2023.